ABSTRACT This Special Issue of Neuropharmacology on psychedelics provides a timely
and comprehensive update on progress following the previous Neuropharmacology Special …

Psychedelic therapy is perhaps the most exciting new development in psychiatry. Not only
does it offer a radical new approach to treatment where mainstream approaches have …

There is a resurgence, some say renaissance, of clinical research on psychedelic
substances after decades of dormancy. Recent studies have produced findings suggesting …

The past 15 years have witnessed an enthusiastic revival of research into the therapeutic
potential of psychedelic drugs (eg psilocybin, MDMA) for people with serious psychiatric and …

Clinical trials of psychedelics have provided support for their potential efficacy and safety.
Although most combined a psychedelic with psychological support akin to psychotherapy …

Abstract The US National Institutes of Health (NIH) convened a seminal first ever
psychedelic drug substance-focused speaker series, from April 22 to June 10, 2021, titled …

In clinical research settings around the world, renewed investigations are taking place on
the use of psychedelic substances for treating illnesses such as addiction, depression …

This article covers the renaissance of classical psychedelic drugs such as psilocybin and
LSD plus 3, 4-methylene dioxymethamphetamine (MDMA—ecstasy) in psychiatric research …

The clinical investigation of psychedelic medicines has blossomed over the last 5 years.
Data from a Phase 3 industry trial and a multicenter Phase 2 industry trial, in addition to …

There is a serious need for novel therapies that treat individuals with depression, including
major depressive disorder (MDD) and treatment-resistant depression (TRD). An emerging …